Dogwood Therapeutics, Inc. (DWTX) News
Follow Dogwood Therapeutics, Inc. (DWTX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Dogwood Therapeutics Q3 Net Loss Narrows as R&D Costs Fall
EQUITY | Nov 05, 2026, 02:04 PM UTC
M
Dogwood Therapeutics Reports Q3 Net Loss of $4.9M
Dogwood reported a Q3 2026 net loss attributable to common stockholders of $4.9 million, or $0.14 per share, versus $15.7 million, or $8.20 per share, in Q3 2025. Halneuron Phase 2b top-line results are expected in Novem
EQUITY | Nov 05, 2026, 01:53 PM UTC
M
Dogwood Therapeutics Reports Third-Quarter 2026 Financial Results
The company says it completed its Phase 2b trial of Halneuron for chemotherapy-induced neuropathy; top-line results are expected in November 2026. Its Phase 2b long-term extension study is fully recruited, with 95 patien
EQUITY | Nov 05, 2026, 01:37 PM UTC
M
Dogwood Therapeutics Announces Third-Quarter 2026 Results
Dogwood Therapeutics reported third-quarter 2026 financial results and said it completed the Halneuron Phase 2b trial in chemotherapy-induced neuropathy. Top-line results are to be released later; timing was not provided
EQUITY | Nov 05, 2026, 01:32 PM UTC
M
Dogwood Therapeutics Raises $5 Million in Share Sale at $1.22
The company agreed to sell 4,098,360 common shares to Sealbond for approximately $5 million in gross proceeds. Closing is expected on or before Oct. 29, 2026.
EQUITY | Oct 19, 2026, 12:53 PM UTC
L
Dogwood Announces $5 Million Private Placement with CK Life Sciences
Dogwood announced a $5 million private placement with CK Life Sciences Int’l., (Holdings) Inc.
EQUITY | Oct 19, 2026, 12:35 PM UTC
M
DWTX Halneuron reports significant, durable pain relief in CINP Phase 2
Halneuron, a synthetic NaV1.7 inhibitor, showed significant and durable pain relief in CINP patients in Phase 2. Company says manufacturing is scalable and a Phase 2b data readout is expected in Fall 2026.
REGULATION | Sep 01, 2026, 06:23 PM UTC
L
DWTX says Halneuron shows durable efficacy in chemotherapy neuropathic pain
DWTX’s Halneuron, a selective NaV1.7 inhibitor, is described as targeting chemotherapy-induced neuropathic pain with durable efficacy and strong tolerability in clinical trials. Company says synthetic TTX manufacturing s
EQUITY | Sep 01, 2026, 05:28 PM UTC
L
DWTX highlights Halneuron potential for chemotherapy-induced neuropathic pain
Halneuron, a selective NaV1.7 inhibitor, is positioned as a first-in-class, durable therapy for chemotherapy-induced neuropathic pain, citing durable efficacy and a strong safety profile in clinical trials.
EQUITY | Sep 01, 2026, 04:08 PM UTC
L
DWTX - Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 20
DWTX - Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026
EQUITY | Aug 17, 2026, 12:30 PM UTC
L
Dogwood Therapeutics reports Second Quarter 2026 financial results
Dogwood Therapeutics (DWTX) announces its Second Quarter 2026 financial results, with no additional figures or guidance included in the provided feed.
EARNINGS | Aug 13, 2026, 12:30 PM UTC